Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
MIRA Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry-Forward Securities
| | Security Type | | Security Class Title | | Fee Calculation Rule | | | Amount Registered | | | Proposed Maximum Offering Price Per Unit | | | Maximum Aggregate Offering Price (1)(2) | | | Fee Rate | | | Amount of Registration Fee | | | Carry Forward Form Type | | | Carry Forward File Number | | | Carry Forward Initial Effective Date | | | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
Newly Registered Securities | |
Fees to be Paid | | Equity | | Common stock, par value $0.0001 per share | | | 457(o) | | | | (3 | ) | | | (3 | ) | | | (3 | ) | | | | | | | | | | | | | | | | | | | | | | | | |
| | Equity | | Preferred stock, par value $0.0001 per share | | | 457(o) | | | | (3 | ) | | | (3 | ) | | | (3 | ) | | | | | | | | | | | | | | | | | | | | | | | | |
| | Other | | Warrants | | | 457(o) | | | | (3 | ) | | | (3 | ) | | | (3 | ) | | | | | | | | | | | | | | | | | | | | | | | | |
| | Other | | Units | | | 457(o) | | | | (3 | ) | | | (3 | ) | | | (3 | ) | | | | | | | | | | | | | | | | | | | | | | | | |
| | Unallocated (Universal) Shelf | | | | | 457(o) | | | | (3 | ) | | | (3 | ) | | | $100,000,000.00 (5 | ) | | | 0.00014760 | | | $ | 11,070.00 | | | | | | | | | | | | | | | | | |
Carry Forward Securities | |
Carry Forward Securities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Total Offering Amount | | | | | | | $ | 100,000,000 | | | | 0.00014760 | | | $ | 14,760 | | | | | | | | | | | | | | | | | |
| | Total Fees Previously Paid | | | | | | | | | | | | | | | | N/A | | | | | | | | | | | | | | | | | |
| | Total Fee Offsets | | | | | | | | | | | | | | | | N/A | | | | | | | | | | | | | | | | | |
| | Net Fee Due | | | | | | | | | | | | | | | $ | 14,760 | | | | | | | | | | | | | | | | | |
(1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock of MIRA Pharmaceuticals, Inc. (the “Registrant”) that become issuable with respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of outstanding shares of Registrant’s common stock. |
| |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee in pursuant to Rule 457(o) under the Securities Act. |
(3) | An indeterminate number or aggregate principal amount, as applicable, of securities of each identified class is being registered as may from time to time be offered on a primary basis at indeterminate prices, including an indeterminate number or amount of securities that may be issued upon the exercise, settlement, exchange or conversion of securities offered hereunder, which together shall have an aggregate initial offering price not to exceed $100,000,000. Separate consideration may or may not be received for securities that are issuable upon conversion of, or in exchange for, or upon exercise of, convertible or exchangeable securities. |
| |
(4) | Estimated solely for purposes of calculating the registration fee. Subject to Rule 462(b) under the Securities Act, the aggregate initial offering price of all securities issued by the Registrant pursuant to the unallocated universal shelf base prospectus (inclusive of any shares of common stock of the Registrant issued pursuant to the sales agreement prospectus) will not exceed $100,000,000. |
| |
(5) | Represents the total of the fee offsets claimed pursuant to Rule 457(p) under the Securities Act for the portion of registration fee previously paid with respect to unsold securities, as set forth in Table 2. The Registrant has terminated the offerings related to the unsold securities associated with the claimed offset. |
Table 2: Fee Offset Claims and Sources
N/A